Case study of Bicycle Therapeutics, which has two venture capital firms and two corporate venturing divisions in its first round of funding.
Venture capital firms are working in tandem with their corporate venturing peers to create a novel approach to investing in start-ups with UK-based Bicycle Therapeutics the vehicle to test out the ideas.
The four initial investors in Bicycle, which was spun out of the UK Medical Research Council’s Laboratory of Molecular Biology in Cambridge in October, include two VCs, Atlas Ventures and SV Life Sciences, and two corporate venturing funds, GlaxoSmithKline’s SR One and the Novartis Venture Fund.
The four…
